麻豆传媒

Use of the PARP inhibitor improved PFS by 19.4 months versus placebo in phase II study

Growing body of data suggest it can be safe and effective in low-risk disease, says expert

Response rate doubles with the noninvasive treatment versus placebo

Subspecialists could see only one patient a week with a new cancer diagnosis, researcher says

MIS roughly halved in the 2 years following the study results, national dataset shows

Dostarlimab and pembrolizumab regimens should be incorporated into practice "as of yesterday"

Novel ADC targeting CDH6 achieves response in nearly 50% of patients

Prospective study in heavily treated population is warranted, researcher says

Overall risk and risk of endometrioid subtype 20- to 30-fold greater in women younger than 35

Adding immunotherapy will change frontline treatment, experts say

High response rates in small studies of immuno-oncology combination, neoadjuvant olaparib

Long-running clinical trial failed to identify any subgroup that fared better with CRT

Pathologic response rises to 73% versus 50% in historical control group

Responses in a fourth of patients, clinical benefit in up to 90%